The investigation needs of a dedication and of a time that sometimes can last several years before reaching results.
Some examples of the advances contributed by projects financed by the Scientific Foundation are:
The neuroblastoma is the most frequent second cause of mortality in the children and it is the most frequent cancer in children younger than five years of age. This investigation proposal is excellent for the children with this type of cancer, since it is going to provide the concept test for the treatment with a guided therapy that is used at present in the adults with breast cancer and hereditary ovary. The proposal is based on the functional similarities of the genes affected in hereditary cancers of breast and ovary with the gene affected in a subtype of neuroblastomas of high risk named ATM. Previously preliminary experiments have been realized with very positive results that endorse the viability of this research project.
Also, this study will provide evidences of the genetic and biological characteristics that help to predict the answer to this therapy, implementing this way a precision medicine to the correct patient. The proposal centers on the characterization of the finished loss or of mutation in the gene ATM like a genetic characteristic that results in the neuroblastomas sensibility to the inhibiting ones of PARP (recipient of the surface of the cellular nucleus). The genómica instability and resistance to the apoptosis caused by the mutation and/or loss of ATM and other genes (TP73) respectively, can modify the susceptibility. to the inhibiting PARP treatment in human cellular lines and in models of rodents. The results that are generated by this preclinical investigation study will serve like foundation for a future clinical essay.
FUNCTIONAL RECREATION OF THE LEUKEMIA INFANTILE SHARP LINFOBLÁSTICA
The osteosarcoma is the most common cancer in bone. It is a complex illness and it can take place on having been created or after bone is consumed, as a result of the aging or alteration of some genes in the normal cells.
These bone tumors spread to other organs, principally the lung, in more than 30 % of patients, which has a fatal prognosis. It is not known with accuracy why the osteosarcoma develops and how it spreads to other organs.
Using mice modified to imitate the illness it humanizes, we think that there exists an abnormal quantity of a few proteins called Wnt, important for the development of the bone and the embryonic development during the gestation. When we block these proteins in the mice that they produce osteosarcomas, these less tumors and more children develop.
The main target of this research project is to understand better why the proteins Wnt can affect to the progression of the osteosarcoma using our modified mice and find, based on it, new therapeutic opportunities.
It is necessary to intensify the investigation in the field of the infantile cancer in order to find more effective alternative treatments to avoid the relapses and with less side effects to shortly and long term.
The percentage of success in the treatment of the infantile cancer has registered an impressive increase in the last decades, although this success turns out to be somehow darkened by the late effects that can develop as a result direct of the treatment. Also, not all the infantile cancers are treated by these therapies.
Our investigation tries to tackle these challenges using animal models and original experimentation methods. In particular, during the latter decade, we have carried out methods of sifted using the common fly of the fruit or Drosophila melanogaster — an organism that the gene ‘Notch’ has affected in a determinant way to the discovery of numerous genes promoters of the included cancer. Our studies, for example, have contributed to a better comprehension of the process of the beginning of the cancer for this oncogene, revealing the connection between Notch and the quinasa named Akt in tumor beginning.
The cooperation between these promoters of the cancer is today unquestionable, and it is estimated sublies 30 % of the cases of infantile sharp leukemia (ALL).
In order to advance the investigation in this field, the present project proposes a concrete and feasible plan to move recent knowledge of our laboratory in possible more effective and sure treatments for the infantile sharp leukemia of high risk of relapse and dependently on these oncogene